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PROGRAM REPORT
The Center of Excellence in Livestock Diseases and Human Health was created in 1984
to promote interdisciplinary activities designed to:
•

Improve the quality of human life through better animal health.

•

Augment livestock disease research capabilities in the College of Veterinary
Medicine and the Institute of Agriculture.

•

Identify and characterize animal diseases that are analogous to human diseases
(animal models of human disease).

•

Develop new strategies for the diagnosis, treatment, and prevention of disease.

Since its inception, the Center has successfully promoted these goals by serving to
promote the development of programs that impact the understanding and
treatment/prevention of livestock and human diseases. The objectives have evolved and
now represent a predominant, contemporary concentration on molecular and cellular
approaches to investigations supporting the general areas of infectious
diseases/population medicine, toxicology, reproduction, host defense, molecular genetics,
and carcinogenesis. All of the Center core faculty contribute to at least one of these areas
of emphasis. The Center promotes the potential of new investigators to develop
competitive research programs and facilitates the efforts of established investigators to
maintain and expand their research efforts. In addition, the Center actively supports the
training of graduate students, veterinary student interns, and postdoctoral research
students.
Center accomplishments for the year 2000-2001 were excellent when measured both as
benchmarks (Table 1) and, perhaps more significantly, as the increasing extramural
funding base (Table 2). The return on the State's investment in the Center as the
ratio of expenditures from extramural grants and contracts to Center appropriation
was 4.4. Grant and contract expenditures exceeded $2.5 million (Table 2). While
this was impressive, the increase in total award funding supporting Center faculty
increased from $10,863,253 the preceding year to $12,760,303, approximately
$2,000,000. This increase was due primarily to significant new grants and contracts
awarded to Drs. McEntee, Rouse, and S. Oliver, although other new valuable grants
and contracts were awarded to Center faculty. The 16 Center faculty averaged
approximately 5 scientific and scholarly publications (74 total) and 3 invited
presentations (48 total) at regional and prestigious national meetings (Table 1).
This report features the accomplishments and activities of investigators and research
teams that constitute the core of the Center. Their achievements serve a crucial function
in promoting the College of Veterinary Medicine, the Institute of Agriculture, and the
University of Tennessee. Furthermore, they continue to ensure that the Center maintains
its strong competitive position and contributes to the fiscal health of our research
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environment. The report endeavors to emphasize the strength of the Center and give a
clear indication of how it meets its objectives.
Research Funding
Important goals of the Center of Excellence in Livestock Diseases and Human Health are
to support researchers and to promote research by a variety of mechanisms. State fiscal
restraints for several years have restricted our ability to recruit and hire competitive
researchers. The Center has had a significant impact over the last three years in
recruitment of researchers with ongoing research programs. The existence of the
Center and its ability to contribute to start-up packages has made the difference in
these recruitment efforts. The Center does not serve as a primary source of research
funding for faculty. The main criteria used for funding proposals include scientific merit,
likelihood of leading to extramural funding and relevance to the Center's objectives.
Proposals submitted to the Center for funding are reviewed by the Research and Graduate
Programs Advisory Committee. The latter has one representative from every department
of the College of Veterinary Medicine. For 2000-2001, "seed" grant funds totaling
$288,550 were awarded to promote research initiatives by Center faculty.
The following projects were supported this past year by the Center:
•

Dr. Frank Andrews. Pathogenesis of acid injury in the non-glandular
region of the equine stomach.

•

Dr. David Brian. Genetic structural elements regulating RNA synthesis
during coronavirus replication.

•

Dr. Mei-Zhen Cui. Mechanisms of lipoprotein induction of tissue factor
gene expression in smooth muscle cells.

•

Dr. James Godkin.
development.

•

Dr. Alan Mathew. Characterization of bacterial resistance elements in
swine herds.

•

Dr. Michael McEntee. Cellular mechanisms of NSAID-mediated
regression in intestinal tumors.

•

Dr. John New. A pilot project to survey rodent populations in the Great
Smoky Mountains National Park for the presence of hantavirus and
Borrelia species.

•

Dr. Jack Oliver. Studies of tall fescue toxin-induced aminoacidemia in
cattle.

Retinoids in oocyte maturation and embryonic
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•

Dr. Steve Oliver.
virulence factors.

Identification and characterization of streptococcal

•

Dr. Barry Rouse. Role of chaperone-bound peptides in the induction of
antiviral CTL responses.

•

Dr. Hildegard Schuller. Effects of NNK on beta-adrenergic growth
regulation of pulmonary adenocarcinoma in vitro.

•

Dr. Terry Schultz. Quantification of the underestimation of toxic
potency in micro scale testing.

•

Dr. Patricia Tithof. Effects of components of cigarette smoke on
endothelial cell and vascular smooth muscle cell arachidonic acid
metabolism and apoptosis. (start-up grant)

•

Dr. Hwa-Chain Wang. Novel intracellular signaling pathways leading to
cell quiescence and apoptosis. (start-up grant)

•

Dr. Xuemin Xu. Untitled start-up grant.

Equipment and Facilities
The Center promotes the research infrastructure of the CVM and the Institute of
Agriculture by participating in the purchase and maintenance of essential research
equipment and through maintenance and renovation of research facilities. Criteria
considered in the allocation of these funds include justification of need, equipment
availability, and the number of investigators who may benefit. Requests from 5
individual investigators for 5 pieces of equipment totaling $35,398 were funded by the
Center this past year. Researchers benefiting from these equipment grants were Drs.
Wang, S. Oliver, Bartges, Rouse, and Brian. In addition, Dr. Hildegard Schuller and
other COE faculty secured a substantial equipment grant from the NIH ($150,000, Table
2) with matching funds ($111 ,448) provided by the Center. This grant supported the
purchase of a state-of-the-art Fascan-Cell SorterlFlow Cytometer which is being used in
support of basic and clinical research projects. Moreover, the Center is providing
technical support for this sophisticated instrument.
Matching funds and technical
support provided by the Center were critical in the success of this application. This
"turbosorter" greatly enhances the research capacity and grant competitiveness of the
Center faculty and is being used also by investigators not previously associated with the
Center.
Renovations funded by the Center of Excellence included extensive repair and renovation
of walk-in coolers in A329A and A307 laboratories in the Veterinary Teaching Hospital.
These coolers are used primarily by investigators participating in the COE. Similarly,
repair and maintenance of several pieces of research equipment were funded by COE
funds. This included an ultracentrifuge and the transmission electron microscope.
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Research Training and Student Awards
The College of Veterinary Medicine funds at least 10 positions for Ph.D. training of
students with a professional medical degree. Some of these positions are based in the
Department of Pathology (as part of their residency/PhD program) and some are awarded
without restriction. Most of these students become linked with Center of Excellence
faculty. These young investigators significantly bolster the achievements of the Center.
Faculty benefiting from these graduate students include Drs. Brian, Tithof, Schuller and
Wang.
An important mechanism by which the Center of Excellence promotes biomedical
research is to provide summer opportunities for veterinary students to do investigational
work in research laboratories in the College of Veterinary Medicine. This past year the
Center funded nine requests from first- and second-year students. The students are
required to provide a summary of their work, which then is entered into a competition
judged by Phi Zeta, the veterinary honorary society. This program is very successful.
Several students have presented their work at national scientific meetings, and numerous
manuscripts detailing results from work done by these students have been submitted for
publication to refereed journals. In fact, over the past five years, this program has
resulted in approximately 30 publications in refereed journals, several with the
students as senior authors. The following veterinary student interns and their (mentors)
and proj ects were supported by the Center during the summer of 200 1:
•

Eric Rundlett (Dr. Davis), "Determining Antibiotic Resistance in Cattle in a
Developing Country".

•

Michael Owston (Drs. Bemis and Kania), "Bacterial Gene Expression".

•

Lisa Miller (Drs. Lane, Bartges, and Mawby), "Urinary Tract Disorders and
Hypothyroidism in Doberman Pinschers, Golden Retrievers, and Labrador
Retrievers" .

•

Pam Wilkins (Drs. Patton and Faulkner), "Diagnosis of Gastrointestinal Parasites
in Free-ranging African Gorillas".

•

Jan McGinn (Dr. Tithof), "Identification of Specific Components of Cigarette
Smoke that Cause Vascular Smooth Muscle Death".

•

Shannon Jarchow (Dr. Schultz), "Quantification of Thyroid Disruption by Micro
scale Testing".

•

Kara Poucher (Dr. Kennedy), "Feline Coronavirus in Nondomestic Felidae".

•

Adrienne Lickey (Dr. Ramsay), "Disease Survey of Domestic Cats
Guatemala: Potential Health Risks to New World Felids".

•

Chuck Bane (Dr. Reed), "Gross Anatomy of the Gray Short-tailed Opossum".

III
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Personnel Changes
Dr. Michael Blackwell assumed the position of Dean of the College of Veterinary
Medicine at the . beginning of the fiscal year. He continued the practice of the two
preceding Dean's by serving as the Director of the Center for the year. Operation of the
Center remained under the supervision of the Assistant Director, Dr. Leon Potgieter,
Professor and Head of Comparative Medicine, who also served as Director of the
Comparative and Experimental Medicine graduate program (CEM). Effective at the
beginning of the next fiscal year, Dean Blackwell appointed Dr. Robert Moore, Professor
and Head of Microbiology, as the Director of the Center and of the CEM program. Dr.
Potgieter led the Center ably for the past several years and is congratulated for promoting
its highly successful status.

Recent recruitments of faculty with a significant research focus will benefit the Center of
Excellence in the future. Over the past approximately three years we have recruited eight
new researchers that will or are contributing to our Center of Excellence. They include
Dr. Hwa Chain Wang (Comparative Medicine Department) who is well funded by NIH
and Dr. Patricia Tithoff (Animal Science) who has received very competitive scores for
her proposals and likely will be funded by NIH in the future. Dr. Joseph W. Bartges
(Department of Small Animal Clinical Sciences) has received substantial funding from a
variety of industry sources and the Morris Animal Foundation. Dr. David Slauson,
former head of the Department of Pathology, recruited Drs. Xuemin Xu and Mei-Zhen
Cui. They brought with them significant research funding from NIH (ROI grants),
American Heart Association and foundations. Their research interests also fall within the
Center's focus. Dr. Hildegard Schuller, the current acting Head of Pathology, recruited
Dr. Howard Plummer whose interest in cell regulation in carcinogenesis and asthma will
complement other investigators in the Center. In addition a search is underway to fill a
Pathology faculty position with an investigator with established interests in cancer
research. Dr. Pam Small joined Microbiology this past year as an internationally
recognized expert in the area of molecular pathogenesis of mycobacterial diseases,
significant problems for human health and cattle industry. Dr. Small was awarded
significant NIH grant support almost immediately and will join the Center as a core
faculty member in 2001-2002. As her work expands into the area of tuberculosis
research, she will do a large portion of her work in the biosafety level 3 core facility in
the Veterinary Teaching Hospital.
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Center Faculty Reports
Following are the reports from the core faculty of the Center. For organizational
purposes the reports are grouped into the two umbrella aspects of the Center's interests,
programs directly applicable to livestock health and population medicine and programs
involving animal and laboratory models applicable to disease.
Livestock Diseases, Population Medicine, and Reproduction

Dr. Frank M. Andrews (equine gastritis)
Collaborators, staff and graduate students: Dr. A.G. Mathew, Dr. C.S. Patton, Dr. J.T.
Blackford, Dr. A.M. Saxton, Dr. S. Murphy, Dr. J. Collins, Dr. R. Torres-Diaz, M.
Sewell, A. Nadeau
Dr. Andrews studies the pathogenesis and mechanisms of gastric ulcer development in a
horse model. Equine gastric ulcer disease (EGUS) is common in horses and has been
implicated in poor performance with significant economic impact on the horse industry.
Performance horses are commonly fed concentrated high-energy feeds that contain high
levels of carbohydrates (starches). These carbohydrates undergo fermentation by resident
bacteria in the stomach that may result in a low stomach pH and release of by-products
such as volatile fatty acids (VFA; acetic, propionic, butyric, and valeric acids). Previous
research in this laboratory established that high concentrations of VF As are produced in
the stomach of horses fed high-energy diets. These acids, due to their high lipid
solubility, diffuse into the non-glandular gastric cells causing acidification and damage to
sodium transport, which leads to cellular injury and gastric ulceration.
Current studies involve examination of fresh viable non-glandular tissue (most
susceptible to gastric ulceration) from the stomach of horses. Tissues are placed in an
Us sing chamber system, which allows measurement of tissue short-circuit current
(sodium flow) and resistance across the tissue. A -decrease in short-circuit current and
resistance are the first indicators of tissue damage, and precede gastric ulcer formation.
These tissues then are viewed under the microscope after special staining to determine
the nature and extent of cellular damage.
Dr. Andrews' research suggests that low pH stomach acidity and volatile fatty acids,
especially butyric, propionic and valeric acids, in contact with the stomach lining leads to
cell damage. Also, valeric acid produced cell damage at a neutral pH. These cells lose
their ability to transport sodium which leads to cellular swelling that, if exposure is long
enough (6 hours) can lead to cell death and gastric ulceration. Examination of stomach
tissues under light microscopy confirmed the presence of cell swelling in the non
glandular squamous mucosa, the area most prone to gastric ulceration in horses.
This research suggests that diets low in fermentable carbohydrates and high in protein
and calcium (alfalfa hay) may be helpful in reducing stomach acid and VFAs aiding in
the prevention of equine gastric ulcer disease. Also, diets could be developed to produce
lower levels of these potentially harmful volatile fatty acids. In addition, the presence of
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valeric acid in the stomach, since it causes damage at neutral pH, may be the reason why
the gastric ulcers in some horses are resistant to treatment.

Dr. David A Brian (coronavirus molecular hiologylpathogenesis)
Fellows and Graduate Students: Dr. S. Senanayake, Dr. K. Nixon, Dr. A. Ozdarendelli,
G.D. Williams, S. Raman, C. Gay, H. Wu.
Dr. Brian's interest in basic molecular biology of viruses has resulted in discoveries of a
fundamental nature for which his laboratory has received national and international
recognition. His research focuses on coronaviruses which cause of some of the most
costly respiratory and gastroenteric diseases of livestock and fowl, and disabling diseases
of people. Efforts to control coronavirus infections have been frustrated by three major
obstacles:
1.
An incomplete understanding of how coronaviruses replicate and persist in
animals.
The ability of coronaviruses to rapidly mutate into new pathogenic
2.
variants.
3.
The generally weak immune responses in animals to coronavirus
vaccination and the logistical problem of inducing protective mucosal
(local) immunity in the vulnerable newborn.
The primary research focus in Dr. Brian's laboratory is the molecular biology of
coronavirus replication. With funding from the USDA and the NIH, and modest support
from the Center of Excellence, they are making an intense effort to understand how five
separate genetic elements in the coronavirus function to regulate production of viral
proteins and progeny virus. Research is being done also on a sixth genetic region, a hot
spot for variability, in an effort to understand the determinants of this process. Genetic
recombination (blending) at this site is a mandatory step used by the virus in the
generation of messenger molecules that encode portions of the virus' genetic material. It
is anticipated that information from these studies will significantly impact the design of
new therapeutic strategies.
Of special interest is how a newly discovered element at one end of the virus gene
regulates replication of the genetic material. The element is a tRNA-like folded structure
(a pseudoknot), that may regulate virus replication by incorporating a cellular protein in
the virus replication machinery.
Therapeutic interruption of such a virus-protein
interaction may lead to a cure of virus infection. Interestingly, one candidate protein in
this interaction is histidyl tRNA synthetase, a factor (auto antigen) in the human disease
polymyositis.
Dr. Brian's laboratory has also discovered a small genetic variant of the bovine
coronavirus (a viral mini genome) that replicates in the presence of "normal" virus. This
minigenome is being experimentally engineered to carry many kinds of potential antiviral
molecules into cells. One molecule is an enzyme (a ribozyme) designed to destroy the
gene on which the virus depends for replication (the polymerase gene). This novel
therapeutic approach would, in theory, cure a virus-infected cell without killing it.
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Dr. Alan G. Mathew (livestock enteric antibiotic resistance)
Staff and graduate students: R. Clift, S. Chattin, D. Arnett, P. Cullen, P. Ebner, K.
Garner, G. Pulliam, 1. Liu

Antibiotics are commonly used in livestock and pets in the US. Therapeutic use of
antibiotics continues to play a major role in combating disease organisms, while
subtherapeutic use in feeds increases animal performance, decreases the numbers of
infectious organisms in the environment, and lowers the prevalence of organisms causing
foodborne illness in humans.
In contrast to the above benefits, some evidence suggests that agricultUral use of
antibiotics may be partly responsible for the emergence of drug-resistant bacteria, which
in turn may decrease the efficacy of similar products used in human medicine. However,
little information is available on strategies for controlling of antibiotic-resistant
organisms. In particular, almost no information is available with respect to modern
livestock production facilities, management, environmental conditions, or drug therapies
that affect resistance in organisms. Because resistance may be transferred to bacteria
from a variety of resistant bacteria and associated hosts, it is important that factors
involved are characterized so that more effective control strategies can be formulated.
A primary research focus of Dr. Mathew's group is to characterize genetic factors
that lead to antibiotic resistance in animal and human pathogens. They also are
investigating how different uses of antibiotics in livestock and pets affect antibiotic
resistance patterns, concentrations, and shedding of food borne pathogens. They hope to
determine the most effective antibiotic therapies and husbandry practices to maintain
animal health, while at the same time limiting prevalence of food borne pathogens and
antibiotic resistance of microorganisms.
A recent accomplishment of his group has been the determination that resistance
to a widely used antibiotic, apramycin is controlled by genes found on bacterial
chromosomes, particularly in non-pathogenic E. coli found in the 01 tract of animals.
Formerly, it had been assumed that such genes resided primarily on extrachromasomal
plasmids which are highly mobile DNA elements frequently found in bacteria. This
information indicates that resistance to apramycin is more persistent in some types of
bacteria, and, thus, strategies for control will need to be revised. They have also
developed a number of molecular techniques to quickly detect resistance genes and
insertion points for those genes in bacterial genes and plasmids. This work has led to a
more specific test for a particularly hazardous strain of Salmonella typhimurium, DTI04,
which carries resistance for at least 5 antibiotics. The PCR-based test can easily and
quickly differentiate between non-typhymurium salmonellae, S. typhimurium, and S.
typhimurium DTI04 providing a powerful tool for epidemiological studies.

10

Other accomplishments of Dr. Matthew's group include the finding that various
animal stressors, including heat and cold, increase the numbers of antibiotic resistant
bacteria associated with livestock. In addition, investigations of the prevalence of
resistant bacteria and food borne pathogens in pets are underway and have already
provided important preliminary data that will ultimately lead to methods to reduce
microbial risks associated with pets and companion animals. Additional work also
continues to define sources and reservoirs of food borne pathogens in livestock units.
Such information will be instrumental in the implementation of on-farm Hazard Analysis
Critical Control Points (HACCP) strategies for control of specific food borne pathogens.

Dr. Jack W. Oliver (bovine tall fescue toxicity)
Co-investigators and staff: Dr. R. Linnabary, Dr. E. Schultze and Dr. B. Rohrbach,
L.K. Abney, E.M. Bailey, M. Cottrell and J. Czarra
Tall fescue toxicosis continues to be the primary grass-related disease in the
United States in terms of economic loss to animal producers, affecting over 8.5 million
beef cows and 700,000 horses. Tall fescue toxicosis is also a costly disease to Tennessee
cattle producers, resulting in an approximate $100 million dollar annual loss due to
unrealized production. Tall fescue is an attractive forage species because of its ability to
withstand drought, poor soil conditions and intensive defoliation from grazing. It is
grown on more than 34 million acres of pasture, but 75% of the pastures are infected with
the endophytic-fungus, Neotyphodium coenophialum, at a sixty percent or greater level.
Most of the infested pastures are in the Southeastern United States.
The endophyte-grass association results in the production of alkaloid toxins
produced by the fungus or by the plant in response to the fungus. The alkaloids are
biologically active causing a decrease in appetite and impaired reproduction and growth
in animals. Endophyte-infected tall fescue has greater forage and seed productivity than
the non-infected variety and is more drought tolerant. At the same time, tall fescue
toxicosis is a costly disease to animal producers, causing severe reductions in weight
gains, milk production and fertility.
Results of studies by Dr. Oliver's group have established that vascular damage is
a central event that occurs when herbivores consume infected tall fescue . As a
consequence of injury to blood vessels, blood flow to tissues is impaired causing
localized tissue damage and thereby affecting the function of body systems. The
abnormalities in blood flow are integrally related to the economic losses encountered by
the cattle industry in the United States. Dr. Oliver has been examining toxicity associated
with purified alkaloids that are suspected of being the primary tall fescue toxins (i.e.
ergine, ergovaline). The long range goal of these studies is to understand how the
individual toxic alkaloids cause damage to tissues of cattle because little is known
regarding which of the alkaloids in tall fescue cause(s) the lesions in this syndrome.
Studies have been completed on analyses of various parameters of blood and
tissues in steers that grazed endophyte-infected tall fescue over a three-year period.
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Markedly suppressed levels of serum copper were recorded in consecutive years, and
copper deficiency may be the basis of the poor haircoats in these cattle. Gamma globulin
(antibody) levels these cattle also were significantly reduced, suggesting that
immunosuppression is an important aspect of the disease too. This infonnation of tall
fescue toxicity in cattle will be important in evaluating anti-fescue toxicosis treatments.
Continued research will be focused on the chronic effects of the two important
alkaloids of toxic tall fescue, ergine and ergovaline. Cattle will be treated with each of
these alkaloids to evaluate their effect on the function of a specific blood vessel receptor
(alpha-2 adrenergic). Dr. Oliver detennined that ergovaline administration at the rate of
0.2 uglkglhour caused the typical decrease in the hormone (prolactin) in blood that occurs
in cattle grazing on fungus-infected tall fescue pastures. Since the lining cells of blood
vessels (endothelial cells) are damaged by exposure to the alkaloids, several
inflammatory mediators associated with endothelial cell injury will be measured in the
serum of the cattle that are infused with ergine or ergovaline.
Laboratory studies with isolated bovine endothelial cells or smooth muscle cells,
grown in culture were treated with various concentrations of ergovaline and ergine. Both
of these alkaloids are toxic to endothelial cells but ergovaline was considerably more
potent. Dr. Oliver's results indicat~ that manipulation of the infection allowing ergine
production in the plant but elimination of ergovaline presence would be beneficial. The
ergine is necessary to convey insect resistance to tall fescue and the toxic effect would be
minimized because the absence of ergovaline. Reducing the toxic effect of ergovaline in
cattle will allow increased use of tall fescue, a forage with excellent nutrient quality, and
root development that helps to control soil erosion. Dr. Oliver's research has been
supported by the Center of Excellence, but his primary support is from the USDA's
National Research Initiative.
Dr. Stephen P. Oliver (bovine mastitis)
Fellows and Staff: R. Almeida, W. Fang, B. Gillespie, M. Lewis, D. Luther, S. Ivey, L.
Coleman.
Research conducted by Dr. Oliver focuses on mastitis in dairy cows caused by
environmental organisms. Several kinds of bacteria are capable of infecting the udder
causing mastitis. These pathogens invade the udder, mUltiply there and produce harmful
substances that result in inflammation, reduced milk production and altered milk quality.
Control of mastitis is extremely difficult because of the many types and sources of mastitis
pathogens that can cause the disease. The National Mastitis Council estimates that mastitis
costs U.S. dairy producers over two billion dollars annually. In Tennessee, losses due to
mastitis may exceed $25 million annually. Thus, mastitis in dairy cows is likely the most
costly disease affecting dairy producers in Tennessee, the U.S., and throughout the world.
Dr. Oliver was the first to show that mastitis in pregnant dairy heifers occurred
frequently near calving and that many of these infections persisted into early lactation. His
research has resulted in a simple, effective and inexpensive method for controlling mastitis
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in heifers. Intra-mammary antibiotic infusion before calving, was shown to be an
effective procedure for:
1) eliminating many infections in heifers during late gestation
2) reducing the prevalence of mastitis in heifers during early lactation
3) for reducing the prevalence of mastitis in heifers throughout lactation.
He documented that a return of $12-$20 for each dollar spent was possible using this
approach.
Several studies over the past 13 years at the UT Dairy Experiment Station involved
collection of almost 200,000 milk samples for microbiological evaluation at intervals before
calving, during lactation and during the dry period. Data from those studies have been
computerized and this mastitis database may be the largest in the world. It now is being
exploited for retrospective studies and will provide valuable information on the spread of
mastitis pathogens, such as Streptococcus uberis and Streptococcus dysgalactiae, in high
producing dairy herds. Recently, they evaluated the influence of mastitis on reproduction in
Jersey cows and found it profoundly impairs reproduction during early lactation.
Dr. Oliver has been actively seeking the identification of virulence (severity) factors
produced by certain mastitis organisms (Streptococcus species) and implications of
immunity to them. In many dairy herds Streptococcus uberis and Streptococcus
dysgalactiae are responsible for a high proportion of mastitis with varying degrees of
severity in lactating and non-lactating dairy cows. Strategies for controlling these mastitis
pathogens are poorly defmed and inadequate. This research focuses on:
1) genetic characterization of Streptococcus uberis and Streptococcus dysgalactiae
2) characterization of Streptococcus uberis and Streptococcus dysgalactiae with
particular emphasis on factors involved in adherence and invasion into
mammary epithelial cells
3) evaluation of immunity after immunization of dairy cows with components of
Streptococcus uberis and Streptococcus dysgalactiae
4) effectiveness of experimental vaccines to Streptococcus uberis and Streptococcus
dysgalactiae mastitis during the nonlactating period
Dr. Oliver's research group has determined that Streptococcus uberis and
Streptococcus dysgalactiae readily adhered to and invaded cells lining the bovine udder.
Chronic infections then may develop, and their intracellular location may protect these
bacteria from anti-microbial drugs and host defense mechanisms. Mastitis pathogens
cultured in the presence of mammary epithelial (lining) cells in the laboratory synthesize
proteins not detected when bacteria are cultured alone. These unique proteins likely are
involved in virulence of bacteria, including their capacity to adhere and invade mammary
epithelial cells. Thus, culture of mastitis pathogens in the laboratory in the presence of
mammary epithelial cells may result in expression of bacterial virulence factors similar to
that which occurs in the animal. This important discovery will be exploited for the
development of vaccines and management of mastitis.
Dr. Oliver's expertise in mastitis and milk quality has led also to a new research
initiative in food safety. The primary goal is to provide comprehensive information on the
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occurrence and distribution of Salmonella, Escherichia coli 015 7:H7, and Campylobacter
jejuni in bulk tank milk, feces of cull dairy cows and the environment in dairies. Antibiotic
resistance patterns and molecular characterization of foodborne pathogens is also being
done.
Dr. Oliver has increased the awareness of scientists, extension specialists, dairy
producers and pharmaceutical companies of the importance of environmental pathogens in
bovine mastitis. Furthermore, he has discovered fundamentally important information that is
critical for controlling the heterogeneous organisms that cause mastitis. Dr. Oliver's
research philosophy is to design and conduct innovative and useful studies and to report to a
wide variety of constituents. The ultimate goal of this research is to enable dairy producers
in Tennessee, the U.S., and throughout the world to enhance the quantity and quality of milk
produced and thus reduce the economic impact of mastitis.
Dr. Oliver's research has been supported for several years by the Center of
Excellence, but his primary funding has been derived from substantial grants from
foundations, FDA and the pharmaceutical industry.

Dr. James D. Godkin (reproduction)
Fellows, Staff and Graduate Students: Dr. D. Eberhardt, T. Livingston, H. King, S.
MacKenzie, M. Roberts
The focus of Dr. Godkin's research group over the past few years has been the
study of proteins that communicate fetal-maternal interactions and result in the successful
maintenance of pregnancy. One important discovery was that interferon-tau, a placental
protein, interacts with the uterus and alters maternal hormonal balance and maintains
early pregnancy in ruminants such as cattle, sheep, goats, and buffalo. Another focus of
Dr. Godkin's laboratory is reproductive efficiency with respect to the effect of growth
factors and certain vitamin A-like proteins (retinoid-associated) and their genes on the
early embryo, ovary, oviduct and uterus.
The major current focus of Dr. Godkin's laboratory is on factors that control
development of the early embryo of domestic livestock. Recently, they made the
remarkable discovery that treatment of animals with vitamin A-like compounds
(retinoids), just prior to ovulation, results in improved viability of embryos that then
develop following fertilization. In addition, his laboratory studies indicated that
treatment of embryos with retinoids dramatically improved embryonic development. The
goals of this research are to improve reproductive efficiency through the use of retinoid
administration procedures, to develop more efficient assisted reproductive procedures and
to determine the mechanisms by which retinoids affect oocyte (egg) maturation,
embryonic development and survival.
This research has the potential to improve reproductive efficiency in livestock and
improve assisted reproductive procedures in humans. It also has an application for the
preservation of endangered species.
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A patent application has been filed covering the use of retinoids in assisted
reproductive procedures with the assistance of the UT Research Corporation. Dr.
Godkin's research has received support from the Center of Excellence which has been
leveraged into substantial funding from the USDA's National Research Initiative.
Animal and Laboratory Models of Disease

Dr. Michael McEntee (cancer modeling)
Collaborators, Staff and Graduate Students: Dr. 1. Whelan, A. Cruikshank, N . Neilsen
Dr. McEntee' s research focuses on defining the relationship between tissue levels
of polyunsaturated fatty acids, their metabolism as bioactive lipids (such as prostaglandin
E 2), and forms of cancer to which they have been linked. In collaboration with a
biochemist in the Department of Nutrition at UT, Dr. J. Whelan, he demonstrated
recently that specific dietary polyunsaturated fatty acids can significantly protect against
the development of intestinal cancer in a mouse model of the human disease. Non
steroidal anti-inflammatory drugs like aspirin inhibit the metabolism of polyunsaturated
fatty acids into various prostaglandins. Their research involved the simultaneous
pharmacologic and dietary manipulation of tissue polyunsaturated fatty acids
concentrations.
Polyunsaturated fatty acids derived from fish oils reduced the incidence of this
form of neoplasia by 50% in comparison to polyunsaturated fatty acids common in the
U.S . diet (i.e. animal fat and vegetable oil). Their research suggested that this protective
effect was specifically attributed to longer chain, highly unsaturated polyunsaturated fatty
acids. Dr. McEntee also demonstrated for the first time in an animal that prostaglandins
produced from the "bad" tissue polyunsaturated fatty acids specifically contributes to
intestinal tumor growth. Inhibition of the metabolism of polyunsaturated fatty acids
found in com oil and red meat to prostaglandins significantly contributes to intestinal
.
.
carcmogeneSlS.
The importance of prostaglandins in production of tumors was subsequently
confirmed in experiments where tumors were eliminated following treatment with an
antibody that specifically inactivates this polyunsaturated fatty acid product.
Prostaglandin E2 acts through specific cell receptors and they have shown that it is
produced by the non-neoplastic part of intestinal tumors of their mouse model (as it is in
humans).
They are currently attempting to characterize the distribution of the
prostaglandin E2 receptors in these lesions in order to better understand the link between
the production/target activity of this specific bioactive lipid and intestinal carcinogenesis.
Recent data suggest that the molecular changes contributing to intestinal carcinogenesis
in humans and their mouse model also occur in pet dogs that develop this form of
neoplasia. This strongly implies that the beneficial effects of dietary and pharmacologic
intervention demonstrated in the mouse model would directly translate to dogs, as well as
humans.
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In addition to the above experiments, studies have been initiated to investigate the
contribution of polyunsaturated fatty acids and their metabolites to another common form
of neoplasia that has been strongly linked to dietary fats in humans, prostatic cancer.
Dr. McEntee receives support from the Center of Excellence, but his primary
funding is derived from the Department of Defense, American Institute of Cancer
Research and Monsanto.
Dr. Barry T. Rouse (herpesvirus immunity and pathogenesis)
Fellows, Staff and Graduate Students: S. Chun, S. Deshpande, S. Kug Eo, U.
Kumaraguru, S. Lee, T. Sobhani, M. Zheng
Dr. Rouse's research deals with the recognition and interaction of the body with
viral infections. This group has studied herpes simplex virus, an agent that affects the
majority of humans. The virus persists indefinitely in infected individuals, and some
suffer periodic lesions which are painful and inconvenient. When such lesions occur in
the eye, they can lead to blindness. Dr. Rouse's laboratory is involved in studies directed
to understand the mechanisms by which herpes simplex infection causes blindness.
Dr. Rouse's approach to understanding the interaction between herpes simplex
virus and the immune system is to exploit model infections such as the mouse system as
an animal model. Their aim is to understand how cells and molecular events set into play
by herpes simplex virus lead to chronic inflammatory lesions or to resolution of disease.
Ultimately, it may prove possible to manipUlate the host defenses either to achieve
protection by vaccines or resolution of injury by substances introduced by gene transfer
technology and capable of influencing the immune response.
In the last year they have used mouse models which have been genetically
manipulated to cause deficient immune systems and thereby to evaluate whether the
ocular lesions are the consequence of an autoinflammatory (self-destructive) reaction.
Their results do not support the latter hypothesis. Instead the evidence indicates that
herpes simplex replication in the eye causes the output of molecules called cytokines and
chemokines which activate certain invading cells of the immune system (T lymphocytes)
to release inflammatory substances. This mechanism is referred to as bystander
activation. Such a mechanism could represent an important component of any chronic
inflammatory reaction.
The other major activity in Dr. Rouse's laboratory is to understand the cell and
molecular events that occur during an immune response to novel DNA vaccines. They
have identified that a process called "cross priming" is the main event in this process and
that it is mediated by a "chaperone molecule" bound to a protein (peptide). They are
exploring the use of chaperone-bound peptides as a unique means of vaccination. This
could have a major impact in the prevention of viral diseases in people and animals.
In studies of herpetic ocular disease, Dr. Rouse's group has found that
neovascularization is an essential event in the pathogenesis of this disease. Moreover,
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they have determined that HSV-induced VEGF is involved in this process and that
intentional diminution of the angiogenic factors production limits the severity of the
viral-induced corneal lesions. Their data document for the first time the essential role of
angiogenesis in the pathogenesis of herpetic stromal keratitis and also indicate that the
therapy of this disease could benefit by procedures which diminish angiogenesis.
The Center of Excellence supports some aspects of this research which is funded
primarily by substantial grants from the National Institutes of Health. Their work has
generated national and international interest, and the laboratory is recognized as one of
the premier viral immunology programs in the country. Dr. Rouse is one of a very select
group of investigators in this country holding three RO 1 NIH awards simultaneously.

Dr. Hildegard M. Schuller (experimental oncology)
Fellows, Staff and Graduate Students: Dr. H. K. Plummer III, Dr. Brian A. Jull, Dr. Y.
Cakir, N. Neilsen, and K. Walker
Lung cancer is the leading cause of cancer deaths in all industrialized countries.
East Tennessee has one of the highest lung cancer rates in the United States. Although
cancers at other organ sites are more than twice as common, their cure rate is
considerably higher. The most common cancer in men is prostate cancer, with a cure rate
of 84%. Breast cancer is the leading type of cancer in women with a cure rate of74%. In
contrast, 158,700 (89.3%) of the 177,700 patients diagnosed with lung cancer in the year
1997 died within 12 months of diagnosis.
Smoking and exposure to second-hand smoke are the most intensively studied and
best-documented risk factors for the development of lung cancer. Contrary to cancers at
other organ sites, the incidence of lung cancer continues to rise in all industrialized
nations. Moreover, teen smoking in the U.S. has increased at an alarming rate, thus
setting the stage for even higher numbers of lung cancer cases 30-40 years from now.
Another important contributing factor to the rise in lung cancer cases is the growing
number of lung cancers developing in individuals never exposed to primary or second
hand smoke. This trend, which has been globally observed during the last two decades in
all industrialized countries, is particularly evident for pulmonary adenocarcinoma. Of the
six types of lung cancer recognized by the World Health Organization classification, two
(small-cell carcinoma and adenocarcinoma) accounts for 90% of all lung cancers, but
30% of these cases do not have a history of exposure to primary or second hand smoke.
The lung cancer "epidemic" is closely related to a globally observed rise in
chronic lung diseases such as bronchitis, bronchiolitis, asthma, emphysema, and chronic
obstructive pulmonary disease. This disease complex, which is often referred to as
"allergies" has the same geographic distribution as lung cancer with which it shares some
risk factors such as smoking and air pollution. Accordingly, East Tennessee, which has
one of the highest lung cancer rates in the U.S., is also often referred to as "the land of
allergies." For all lung cancer types, chronic lung disease has been identified as a risk
factor even without a history of exposure to smoke.
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Dr. Schuller's research has been dedicated to the study of lung cancer for over 20
years. It is her belief that effective strategies for the prevention and therapy of this
disease complex can only be based on an in-depth understanding of the regulatory
mechanisms which govern the growth of normal lung cells and the cancers arising from
such cells. In contrast to other laboratories that are searching for the "magic molecular
event" responsible for the genesis of all lung cancers, she hypothesized that different lung
cell types and different types of lung cancer may be governed by different regulatory
mechanisms, which in tum may be affected differently by known risk factors for the
disease.
Dr. Schuller's achievements in lung cancer research have been recognized
nationally and internationally. Her research has been supported by the Center of
Excellence, but her primary support comes from substantial grants of the National Cancer
Institute and the pharmaceutical industry.
Dr. Schuller's group previously determined that the growth of small cell lung
carcinoma and the cell of origin of this cancer type (pulmonary neuroendocrine cell) is
regulated by a specific cell surface receptor (nicotinic acetylcholine) which has an
important biochemical function (calcium channel). She found also that the tobacco
specific carcinogenic product (NNK) activates this receptor with high affinity. Binding
of this product to the receptor causes a release of a biochemically active substance
(serotonin) by these cells and that this substance markedly stimulates cell division when
it is taken up by other cells. This is an important finding because it links, for the first
time, the stimulation of a specific receptor by a tobacco-specific toxicant resulting in the
activation of a series of cell-specific events that may result in uncontrolled growth.
Experiments are now underway to test the hypothesis that substances which inhibit the
re-uptake of serotonin will protect against the development and spread of small cell lung
carcinoma. These drugs are already approved for the treatment of psychiatric diseases
and migraine and could immediately enter clinical trials in smokers and small cell
carcinoma patients.
Laboratory studies with various cultures of small cell lung cancer cells and
pulmonary neuroendocrine cells suggest that smoking or chronic exposure to the product
NNK, increases the concentration of the target receptors on these cells. Dr. Schuller now
is working with Dr. Kabalka of the Department of Chemistry on the development of
novel cancer imaging agents which selectively bind with high affinity to this receptor that
will allow for a selective and highly sensitive detection of small cell carcinomas in people
(by positron emission tomography). This will constitute an important clinical application
of her research.

Dr. Terry W. Schultz (toxicity modeling)
Staff and Graduate Students: G. Sinks, B. Gregory, J. Seward, and E. Hamblen
Research in the Biological Activity Testing and Modeling Laboratory focuses on
the development of databases for structure-toxicity modeling and the development and
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validation of such models. The values of structure-toxicity models lie in their ability to
predict toxic potency from molecular structure. This means that hazard assessment can
be conducted while conserving time, manpower, resources, and animals.
Toxic potency is related to the uptake of the toxicant from the environment and its
interaction with certain molecular sites of action. Since certain properties (such as
hydrophobic, electronic, and steric factors) are related to molecular structure, Dr.
Schultz's group focuses on identifying global descriptors of such properties that are best
in modeling of uptake and interaction. Previous work by Dr. Schultz's group have shown
that the site of action for toxic events is the cell membrane. In the case of covalent
events, it is soft nucleophiles associated with membrane-bound proteins, whereas, in the
case of non-covalent events it is the fatty acids of the membrane lipid bilayer.
The Biological Activity Testing and Modeling continues to make excellent
progress in the development of a better understanding of chemicals that mimic estrogens.
They have, with help from the Center, developed one of the largest single-endpoint
databases for xenoestrogens in the world. From these data, Dr. Schultz and his
collaborators have developed a series of molecular structural indicators that allow for the
rapid screening of large sets of industrial chemicals for those that have the potential to
cause endocrine disruption.
Work also continues on standardizing the Saccharomyces cerevisiae-based lac-Z
reporter assay as an in vitro assay, which allows for the quantitative assessment of
chemicals that alter estrogen receptor-mediated transcriptional activity. The estrogenic
activities of 17-B-estradiol, biphenyl, chlorinated biphenyls (CB) and Aroclor mixtures
have been examined. Results suggest that the use of plastic microtiter plates in toxicity
testing with strongly hydrophobic chemicals may result in an underestimation of toxicity.
Using the modified yeast estrogen assay, full agonist activity was observed for 4-CB,
2,4,6-CB, and 2,5-CB, while each of the Aroclor mixtures were only partial agonists.
The equivalent ECso values in ppm were in environmentally relevant concentrations of
biphenyl (19 ppm), 4-CB (4.5 ppm), 2,5-CB (21 ppm), 2,4,6-CB (0.8 ppm), Aroclor 1221
(2.9 ppm), Aroclor 1242 (0.65 ppm), and Aroclor 1248 (2.3 ppm).
Other recent achievements by this group include improvement in descriptor
selection for the prediction of toxic potencies of electrophiles. Specifically, Quantitative
Structure-Activity Relationships (QSARs) relating toxic potency with hydrophobicity
quantified by the l-octanollwater partition coefficient and electrophilic reactivity
quantified by the molecular orbital parameters, either the energy of the lowest occupied
molecular orbital or maximum acceptor superdelocalizability reveals maximum acceptor
superdelocalizability to be the better electrophilic parameter for modeling of industrial
aromatic chemicals.
Patricia K. Tithof(cardiovascular physiology and toxicity)
Collaborators, Staff and Graduate students: Dr. M. Peters-Golden, Dr. H. Schuller, Dr.
H.C. Wang, Dr. R. Donnell, M. Elgayyar, M.A. Barnhill
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Dr. Tithors research program in cardiovascular physiology concerns the effects
of specific components of cigarette smoke on the biology of blood vessel lining
(endothelial) cells and metabolism of a potent physiological chemical messenger,
arachidonic acid. The latter is a fatty acid that is present in high quantities in the
membranes of all cells and is a substrate for the production of eicosanoids, a family of
biologically active lipid mediators. The latter have an important role in several diseases
including asthma, arthritis, cancer and atherosclerosis.
Smoking, which greatly augments the process of atherosclerosis, increases the
risk for heart attack or stroke by as much as 50%. Recent epidemiologic studies indicate
that a high fish diet or frequent use of aspirin significantly decreases mortality rates due
to heart attacks in heavy smokers. Fish contains high levels of certain fatty acids, which
decrease the availability of arachidonic acid and also inhibit the production of
arachidonic acid-derived eicosanoids. The protective effects of these fatty acids and
aspirin against smoking-induced atherosclerosis suggest that components of cigarette
smoke stimulate the arachidonic acid pathway. However, no previous studies have
focused on the specific components of cigarette smoke responsible for this effect.
Several compounds are contained in high concentration within the tar fraction of cigarette
smoke. These include methylanthracenes (1,500 ng/cigarette), phenanthrene (362
ng/cigarette) and benzo(a)pyrene (25 ng/cigarette). Benzo(a)pyrene accelerates the
development of atherosclerosis in animal models.
Endothelial cells form a single cell layer lining the blood vessel wall. Endothelial
cell death and loss is a critical and important event in the early development of
atherosclerosis. Loss of the endothelial cell layer results in inflammation of the vessel
wall, vasoconstriction and clot formation; events important in the development of heart
attacks and strokes. Previous studies indicate that cigarette smoking increases the rate of
endothelial cell loss; however, neither the mechanism of cell death nor the specific
components of cigarette smoke responsible have been elucidated.
These studies indicate that exposure of porcine aortic endothelial cells or human
coronary artery endothelial cells to these compounds in cigarette smoke causes release of
arachidonic acid. Furthermore, this release of arachidonic acid is associated with loss of
endothelial cell viability through stimulation of a process known as apoptosis or
programmed cell death. Apoptosis induced by these compounds can be inhibited by the
fatty acid, eicosapentaenoic acid, which exists at high concentrations in fish. These
results suggest that methylanthracenes, phenanthrene and benzo(a)pyrene may be
important components of cigarette smoke that augment atherosclerosis through a process
that involves arachidonic acid-mediated killing of endothelial cells.
Dr. Tithof also has initiated studies to investigate the effects of derivatives of
nicotine on endothelial cell function. A derivative of nicotine, NNK, plays an important
role in smoking-induced lung cancer. Recent studies in collaboration with Dr. Hildegard
Schuller suggest that NNK induces tumor formation by a mechanism that involves
release of arachidonic acid by stimulation of certain cell receptors (beta-adrenergic). The
finding that NNK binds to beta-adrenergic receptors has important implications
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concerning a potential effect of NNK on the cardiovascular system. Evidence indicates a
role for the beta-adrenergic system in the cause of atherosclerosis because beta
adrenergic blocking agents prevent endothelial cell injury Beta-adrenergic blockade also
reduces endothelial cell injury induced by cigarette smoke.
The effects ofNNK on endothelial cell viability were investigated by Dr. Tithors
group. NNK, at very low concentrations (100 nM) caused apoptotic cell death of
endothelial cells. Their results suggest that it was the result of NNK binding to beta
adrenergic receptors and that the arachidonic acid cascade was involved.
These studies provide novel findings concerning the effects of specific
components of cigarette smoke on endothelial cell function and suggest a novel
mechanism by which cigarette smoke augments atherosclerosis. These studies may
contribute to the development of effective measures for preventing cardiovascular
complications in smokers. Moreover, identifying specific components of cigarette smoke
that augment disease may lead to the development of safer cigarettes. These strategies
may be particularly important because the incidence of smoking continues to rise, despite
intensive efforts to educate people about the hazards of smoking.
Dr. Hwa-Chain R. Wang (molecular oncology)
Fellows: K. Fecteau, 1. Mei, Y. Sun, M. Tan

Dr. Wang's long-term research goals concerns tumor-specific intracellular
molecular signaling networks and to uncover signaling pathways that can be induced by
anticancer agents to lead cancerous cells into programmed cell death (apoptosis) or
growth arrest (cell quiescence).
Short-term goals are to identify intracellular signaling elements whose activation
is involved in induction of apoptosis or growth inhibition of cancer cells. A corollary to
this is to identify novel anticancer agents, which may selectively induce apoptosis of
cancer cells while sparing normal cells. Ultimately, he expects to apply the
understanding of intracellular signaling control to anticancer therapeutics and prevention.
Currently, Dr. Wang focuses on three projects. The first is to understand the
molecular and cellular function of a family of novel intracellular enzymes (Krs and QIK),
which are induced in resting cells and cells undergoing programmed cell death. The
second is to study molecular and biological activities of a novel natural anticancer agent
(FR90 1228), which selectively induces programmed cell death of cancer cells. The third
is to study changes in molecular and biological properties of human breast cells during
development into cancerous stages induced by tobacco-related carcinogens.
Dr. Wang has identified a family of novel enzymes (kinases: SAMKJKrs1 and
QIK) that are activated in normal resting cells, in quiescent cells, or in cancerous cells
undergoing programmed cell death as a result of a variety of physiological, chemical or
physical stresses. QIK is an active form of gene products of the Krs 1 gene. Induction of
QIK activity is involved in establishing cell quiescence but additional activation may
result in cell death. He is investigating the molecular and biological roles of these
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enzymes in cancer development and programmed cell death. Uncovering the apparent
novel signaling pathway that cross-links cancer development of cells to programmed cell
death should be directly exploitable for development of anticancer therapeutics.
Investigation into the molecular mechanisms of potential anticancer therapeutic
agents on a variety of cancer cell types particularly human breast cancer cells is ongoing.
Cancerous mouse embryo cell cultures and various human tumor cell cultures are used to
screen anticancer agents. Studies on the molecular effects of a novel natural anticancer
agent FR901228 on different intracellular metabolic signaling pathways should uncover
the mechanism of this agent to selectively induce programmed cell death in cancerous
cells. Dr. Wang determined that at least five important intracellular metabolic signaling
pathways including the QIK pathway are affected. The information will be a basis for
clinical trials using FR901228 in combination with other anticancer agents.
To mimic long term exposure of cells to the tobacco-specific carcinogen NNK,
cultured human breast epithelial MCFI0A cells were treated with low doses of NNK
repeatedly. Cell clones which acquired tumor properties were isolated and subjected to
studies of alterations in signaling pathways and cell growth. This is a pilot project to
establish biochemical evidence of tobacco-specific carcinogens in the induction of
human breast cancers.
Dr. Wang's research is supported by the Center of Excellence, but his primary
funding source is the National Institutes of Health (National Cancer Institute and National
Institute of Dental Research).

Dr. Xuemin Xu (molecular basis ofneurodegenerative disease)
Staff and Graduate students: G. Mao, Ph.D., Y. Shi, W. Gao, and E. Laag
The long-term goal of Dr. Xu's research is to understand the molecular and cellular
mechanism of Alzheimer's disease, and the formation of senile plaques, the pathological
hallmark of this disease. His group is conducting two projects. One is to determine the
pathological function of a substance (presenilin 1) in brain degeneration and the genesis of another
substance (amyloid) observed in Alzheimer's disease. The other project is to determine the role of a
certain protein (apolipoprotein E) in the formation and clearance of another protein involved
Alzheimer's disease CI3-amyloid peptide).
Alzheimer's disease is a progressive degenerative disorder, characterized by memory loss,
confusion, and a variety of cognitive disabilities. An estimated four million American suffer from
Alzheimer's disease. It is the fourth major cause of death in the United States following heart
disease, cancer, and stroke. Alzheimer's disease is the third most costly disease in the U.S. With
the rapid growth of the senior population, Alzheimer's disease poses, besides its tragic personal
impact, serious problems to families, caregivers, government and health care in institutions.
Molecular genetic analysis of familial (heritable) Alzheimer's disease has led to the
identification of three Alzheimer's disease-causative genes, those of l3-amyloid precursor protein,
presenilin 1, and presenilin-2. A fourth gene encoding apolipoprotein E has also been associated
with Alzheimer's disease as a risk factor but not as a causative gene for Alzheimer's disease.
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Among these Alzheimer's disease -causative genes, mutations in presenilin 1 gene account for the
majority of the known cases of familial Alzheimer's disease. Presenilin 1 has been implicated in
two pathological events: (1) the generation of amyloid-~ peptide, which is the building block of the
toxic "plaques" characteristic of brain tissue from patients with Alzheimer's disease, and (2)
programmed cell death, or apoptosis, a natural process in which unneeded or worn-out cells
commit suicide. However, questions regarding the mechanisms by which the mutations in
presenilin 1 proteins alter ~-amyloid precursor protein processing and cause programmed cell
death, as well as the normal function of presenilin 1, remain to be answered, which is the goal of
their current research project.
Recent work resulted in the identification of a novel molecule (PSAP) which is capable of
inducing programmed cell death, one of the mechanisms of neuronal cell death observed in
Alzheimer's disease brains. It reacts specifically with presenelin 1. This finding established for the
first time the molecular link between presenelin 1 and programmed cell death. Currently, we are
conducting the experiments to determine the role presenelin 1 has in regulating PSAP-induced
programmed cell death and with other Alzheimer's disease protein structures such as amyloid
plaques and neurofibrillary tangles. This study will contribute to understanding the pathological
function of presenilin 1 and will provide new insight into the mechanism of Alzheimer's disease.
This study may also lead to the identification a new therapeutic target of Alzheimer's disease
treatments.
Dr. Xu's studies in exploring the role of apolipoprotein E in ~ amyloid peptide formation
suggests that these substances bind together to form complexes that interfere with the function of
a critical enzyme a-secretase. The binding of apolipoprotein E to newly generated ~ amyloid
peptide also may play a role in determining whether the latter is deposited or cleared. These
studies will lead to a better understanding of the mechanism by which the apolipoprotein E is
involved in Alzheimer's disease.
Dr. Xu's experiments are conducted with laboratory models, including brain
(glial) cells containing the genes of apolipoprotein E and for amyloid precursur protein
and in a yeast two-hybrid system. Because mutations in the presenilin 1 gene are
associated with the majority of familial Alzheimer's disease, these studies may provide
important information for the early diagnosis and therapy of this disease.
Dr. Xu's work is funded by grants from the National Institutes of Health, Sigma
Kappa and by the Alzheimer's Association. He receives support also from the Center of
Excellence.

Dissemination of Research to the General Public
Dr. Nancy Howell
One important function of the Center of Excellence is to provide information to
the general public. This information may increase the public's awareness of research and
may provide individuals with valuable results that may improve their lives or their
agribusiness.
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To distribute information the College of Veterinary Medicine uses several
methods. A general newsletter is distributed twice a year throughout Tennessee and
beyond, highlighting research activities. Features concerning on-going research, in
addition to results from concluded research projects, are included in the publication,
Veterinary News, which is written for general audiences. Features also appear in other
University of Tennessee publications, including UT Agriculture, UT Alumnus and
Tennessee AgriScience.
In addition, news releases are distributed to state media and to regional and
national media. Television and print publications produce numerous features about the
College each year, many related directly to research conducted through the Center of
Excellence. Public displays about the College frequently include highlights of COE
research. Center of Excellence researchers are invited to share their research not only
professionally, but as speakers to commodity groups, civic groups and other interested
individuals.
Research is a component of the College's web site, including COE projects such
as the tall fescue toxicity research and other research projects.
Dissemination of research results through the news media helps inform the public
and provides citizens with a better understanding of the practical applications of science
in their daily lives.
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FUTURE PLANS

Much of the Center's efforts during the present year (2001-2002) and next will
concentrate on promoting the development of newly recruited investigators and in the
promotion of initiatives to enhance the research capacity and direction of the Center.
This year the Center is expending $322,500 to fund 13 projects proposed by investigators
in the College of Veterinary Medicine and in the College of Agriculture and Natural
Resources. In addition equipment grants totaling approximately $150,000 have been
approved. Objectives for the two years are listed and explained as follows:
•

The Center will actively seek areas for enhanced research possibilities to support
its objectives. As an example, in December 2001 the Center sponsored a
"brainstorming" session attended by representatives of the clinical departments of
the College of Veterinary Medicine, biomedical engineering and material science
faculty of UT's College of Engineering, and administrators from ORNL's
Materials and Ceramics Division. Focus groups were formed to continue the
interactions with the intent to determine areas for collaborative efforts. Plans
include inviting a representative from the newly created National Institute of
Biomedical Imaging and Biomedical Engineering to discuss areas of funding
interest. Additional plans include a planning session with a DARPA official to
explore funding opportunities in the bioterrorism arena.

•

The Center will explore possibilities to interact cooperatively with other UT
centers to promote joint research interests. As an example, the previously
mentioned biomedical engineering focus groups involve faculty in the THEC
Center for Materials Processing and Center for Environmental Biotechnology. In
addition, the Center is currently supporting a project jointly funded with the Food
Safety Center.

•

The Center will participate conceptually and materially in strategic planning to
develop areas of investigative strength in the College of Veterinary Medicine and
the UTIA.

•

The Center will increase its involvement in research training of veterinary
students and graduate students through the introduction of matching travel grants
and the increased use of stipend upgrades to help in the recruitment and retention
of top quality graduate students.
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TABLE 1

CENTER OF EXCELLENCE IN LIVESTOCK DISEASES
AND HUMAN HEALTH BENCHMARKS OF FACULTY ACCOMPLISHMENTS

2000
Actual

Average

Number of:
Articles
Books or Book Chapters
Published Proceedings
Total Publications
Abstracts

45
2
27
74
14

(2.8)
(0.12)
(1.7)
(4.6)
(0.9)

Invited Participation at:
Regional Meetings
National Meetings

20
28

(1.25)
(1.8)

Faculty in Center

16

Number of Visitors

6

27

TABLE 2
RESEARCH PROJECTS FUNDED EXTERNALLY
REPORT PERIOD 2000-2001

TOTAL AWARDED

ESTIMATED
EXPENDITURES
$170.11

PROJECT DIRECTOR

TITLE OF GRANT

FUNDING AGENCY

Frank Andrews

The role of volatile fatty acids and calcium in
gastric ulcer disease

Grayson-Jockey Club Research
Foundation

$38,475
04/01/01-03/31/02

Pathogenesis of acid injury in the non-glandular
region of the equine stomach.

Grayson-Jockey Club Research
Foundation

$37,110.00
04/01/99-03/31/01

$13,111.20

Funding for a summer veterinary student and a
clinical project: Determination of maintenance
energy requirements of client-owned dogs

Ralston Purina

$10,000.00
OS/24/99-08/31/00

$7,908.14

Comparison of two dietary approaches for
managing canine chronic renal failure

lams

$29,522.00
04/01/99-07/01102

$4,973.84

Pentosan polysulfate sodium in the treatment of
idiopathic feline lower urinary tract disease.

DVM Pharmaceuticals

$133,112.00
09/12/97-08/31/01

$14,413.31

Influence of diet on urine saturation with struvite in
healthy cats

Ralston Purina

$9,594.00
10/01197-10/31/00

$1,703.51

Influence of diet on glycemic control in dogs with
spontaneous insulin-dependent diabetes mellitus

Ralston Purina

$6,093.00
10/01/97-10/31/00

$38.29

Influence of alkalinization on urinary saturation
with calcium oxalate and struvite, and bone mineral
density in cats

Morris Animal Foundation

$25,000.00
09/01/97-03/31/00

$8,560.00

APR studies

Hills Pet Nutrition

$13,500.00
11/01197-10/31/04

136.13

Bovine coronavirus vector for mucosal immunity to
phaemolytica leukotoxin

USDA

$140,000.00
09/15/95-09/30/00

$44,103.33

Mechanism(s) of coronavirus RNA replication and
packaging

National Institute of Allergies and
Infectious Diseases

$586,309.00
07/01/96-06/30/0 I

$117,969.08

Joseph Bartges

David Brian

$240,000.00

$19,735.79

USDA

$215,000.00
09/01/99-08/3I/03

$19,969.00

Laboratory tests for vaccine development

Pfizer

$32,366.81
7/15/99-7/31/01

$28,081.36

Ophidian paramyxovirus infection

American Zoo & Aquarium Assoc

Mei-Zhen Cui

Scientist development award

American Heart Association

James Godkin

The role of retinol in oocyte maturation and early
embryonic development.

Stephen Kania

Alan Mathew

Michael McEntee

Jack Oliver

oI/O 1/98-12/31/0 1

$16,900.00
1% 1/98-9/30/00

$4,638.87

Analysis of coronavirus from cheetahs: Genetic
analysis, epidemiology, and detection of infection

American Zoo & Aquarium Assoc
(Co-PI)

$14,500.00
9/1/00-8/31/0 I

$0

Genetic Characterization of Coronavirus

Morris Animal Foundation (Co-PI)

$14,500.00
9/1/00-8/31/01

$10,959.11

Effects of environment and management on
persistence of antibiotic resistance in bacteria from
swine

The International Life Science Institute

$62,789.00
09/0 I/99-08/3I/00

$42,935.07

Effect of dietary components on intestinal
microflora

lAMS

$72,434.00
04/I/00-07/1/02

$49,212.52

Characterizing the origin and transfer of antibiotic
resistance

National Pork Producers

$31,690.00
04/01/00-4/01/0 I

$29,491.74

Effect of n-3 and n-6 polyunsaturated fatty acids on
growth and progression of prostatic cancer in vivo

DOD-Army

$312,938.00
04/15/00-05/14/03

$16,865.44

In vivo effects ofresveratrol during early stages of
intestinal tumorigenesis

American Institute of Cancer Research

$75,952.00
07/01/99-06/30/0 I

$31 ,511.69

Role of arachidonic acid and PGE2 as key
mediators of intestinal tumorigenesis in vivo

American Institute of Cancer Research
(Co-PI)

$158,484.00
7/99-6/01

$130,540.28

Chemoprevention of intestinal tumorigenesis in the
Apc Minl+ mouse by the inhibition of avB3
integrin

Pharmacia (Co-PI)

$24,739.00
1% 1/00-1 % 1/0 1

$11 ,903.70

Role of cycJooxygenase-l and/or -2 in the
mechanism of intestinal tumorigenesis

Pharmacia (Co-PI)

$245,398.00
1% 1/00-09/30/0 1

$105, 150.28

Reactivity of bovine vasculature to Ergovaline and
Ergine oftoxic tall fescue

USDA

$188,000.00
10/01/97-09/30/00

$28,875.94

Sex hormone concentrations in dogs with adrenal
hyperplasia syndrome treated with melatonin

Morris Animal Foundation (Co-PI)

$8,189.00
09/01/00-08/31/02

$4,029.35

Stephen Oliver

Rapid, specific test for salmonella subtypes

National Pork Producer's Council

$29,150.00
06/01199-07/31/00

$2,925.55

Reproductive performance and reproductive
disorders in Jersey cows

American Jersey Cattle Club

$543,663.00
04/01199-04/01/00

$124,512.64

Development of chronic streptococcus uberis
intramammary infections in lactating dairy cows

Pharmacia and Upjohn

$56,258.00
01101199-12/31/00

$36,086.69

Evaluation of the Uterine Environment During
Clinical Mastitis in Lactating Jersey Cows

American Jersey Cattle Club (Co-PI)

$5,500.00
04/01100-04/01101

$3,342.89

Evaluation and use of BAMlFDA and rapid
microbiological methods for on-farm surveys

Food and Drug Administration (Co-PI)

$475,610.00
09/30/98-09/29/01

$108,575.20

Evaluation of safety, specific immune responses,
duration of immunity, and protection in dairy cows
experimentally infected with Streptococcus uberis

Pfizer

$237,376.00
10/25/00-10124/02

$99,280.56

Molecular genetics of Streptococcus uberis as it
relates to its ability to cause mastitis in dairy cow

Pharmacia and Upjohn

$150,000.00
08/01100-07131105

0

Efficacy of mastic ide for the treatment and
prevention of teat lesions during the winter months

Sporicidin International

$33,738.00
09/01100-08/31/01

$6,393.53

Evaluation of safety, specific immune responses
and protection in experimentally infected dairy
cows following administration of a S. uberis
bacterin

Pfizer

$85,000.00
07/12/00-04112/01

$81,573.89

Does clinical mastitis reduce steroidogenic function
ofthe preovulatory follicle in lactating jersey cows

American Jersey Cattle Association
(Co-PI)

$6,500.00
04/01101-04/02/02

$29,254.00

Barry Rouse

Hildegard Schuller

Terry Schultz

Carla Sommardahl

$124,746.00
open

$381.00

National Institute of Allergy and
Infectious Diseases - Nlli

$1,656,250.00
01/01/01-12/31105

$55,065.09

Mechanisms of herpetic stromal keratitis

National Eye Institute - Nlli

$1,311,151
09/30/97-09/29/02

$181,077.35

Biodelivery sciences

Biodelivery Sciences

$12,000.00
open

$0

HSP peptide complexes as a putative vaccine
against herpes simplex virus

Antigenics Agency

$16,620.00
04/15/99-04/14/00

$28,860.87

Vaccination against herpes simplex virus

National Institute ofAllergy and
Infectious Diseases- Nlli

$1 ,396,346.00
03/01/00-02/28/05

$230,828.19

Transplacental pancreatic carcinogenesis by NNI

National Institute of Health

$1,001,479.00
08/01/96-07/31/01

81,242.69

FACS Vantage SE Cell Sorter/Flow Cytometer

National Center for Research Resources

$150,000.00
04/01/00-03/31/01

$150,000.00

Development of a bioremediation risk assessment
scheme

US Environmental Protection Agency

$59,199.00
09/94-09/98

$20,000.00

Microbial transformation and molecular toxicology
of estrogens

Water Resources Research Institute (CoPI)

$295,334.00
12/07/98-12/06/00

$64,036.00

The Role ofbioavailability in determining
acceptable limits for the bioremediation of
polychlorinated biphenyls

$441,037.00
01/01/97-05/31/00

$160,053.00

U.S. Department of Energy

Ecotoxicity of organic chemicals

Proctor and Gamble

$6,600.00
11/0199-10/31/01

0

Degradation of natural estrogens in wastewater
treatment facilities

University of Mississippi

$25,400.00
09/01/97-10/31100

$25,397.00

Molecular analysis ofPKD in the TGN737RPW
mouse

Nlli

$385,901.00
07/01197-07/01101

$96,897.45

Herpes zosterfilization

Smith-Kline Biological

Immunity mechanisms in herpesvirus infections

Hwa-Chain Wang

XueminXu

TOTALS

Pathway leads to apoptosis in SCR-transformed
cells

Nlli

$517,520.00
01101198-12/31102

$57,2lO.75

Biochemical evaluation of the functionality of
mutated TBR-II and TBR-I receptors

Ohio State University

$192,453.00
09/15/98-06/30/03

$38,594.79

Biomedical applications of Conrex enhancer

Conrex

$14,910.00
11115/00-12114/01

$5,183.96

Role of APOE in beta amyloid formation

Sigma Kappa

$30,000.00
11101198-10/31100

$4,754.14

Role of apoE App processing

Alzheimer's Association

$80,000.00
08/01198-12/31100

$33,938.73

Role of apolipoprotein in AD amyloid formation

National Institute of Neurological Disease
and Stroke

$677,968.00
05/01199-04/30/02

$lO6,766.67

$12,760,303.00

$2,579,219.71

Schedule 7
CENTERS OF EXCELLENCE/CENTERS OF EMPHASIS
ACTUAL, PROPOSED, AND REQUESTED BUDGET
Institution

~ol~le~g~e~m~V~e~re~r~ln~a~ry~Me~d~~~ln~e~______________________ Cenmr

Livestock and Human Health

'0

2000-2001 Actual

'.'7~

Matching

Teul

Appropr.

Matching

Total

ApprOpr.

:"

.~;G" ~1:"

•

·It

2002-2003 Req~ "

2001-2002 PropoHcI

Matching

.f~"~~ "
!!" Appropr, ".

,;F.1

.:'

,

T~ ,

265,250

530,500

795,750

265,250

530,500

795,750

278,082

557,456

835,538

Faculty

23,318

46,637

69,955

31 ,712

63,425

95,137

31 ,672

63,492

95,164

Other Professional

90,991

181 ,983

272,974

26,490

52,979

79,469

81 ,182

162,741

243,923

Clericall Supporting

13,644

27,289

40,933

55,879

111 ,758

167,637

10,250

20,548

30,798

Assistantships

21 ,937

43,874

65,810

22,400

44,800

67,200

21,015

42,128

63,143

149,891

299,782

449,673

136,481

272,962

409,443

144,119

288,909

433,028

68,451

102,676

26,483

52,967

79,450

33,145

-f~177;"

Expenditures
Salaries

Total Salaries
Fringe Benefits

34,225
'~

I'"

'-,

'-

!(>

.'

66,289
"._', :

'1('

"".

99,434

..

I '"',~ ~>."",,;

184,116

368,233

552,3.0

I', 162,964

325,929

488,893

Travel

3,114

6,229

9,343

1,360

2,720

4,080

0

Softwcre

2,270

4,541

6,811

0

0

64

129

193

0

0

Other Supplies

42,674

85,348

128,022

53,441

106,881

160,322

34,334

68,824

103,158

Equipment

48,949

97,897

146,846

50,000

100,000

150,000

52,639

105,279

157,918

Maintenance

13,348

26,694

40,042

6,167

12,333

18,500

14,000

28,000

42,000

Scholarships

1,920

3,838

5,758

2,500

5,000

7,500

0

Tdal Personnel

35$,1"

~, 532;*~ '

Non.personnel

Books & Journals

Consultants

0

0

0

Renovation

0

0

0

Other (Specify)

0

0

0

825

1,650

2,476

0

0

Printing & Duplatlon

52

103

155

0

0

Publations , Reports

97

194

291

Cont&SpSvc

Tdal Non-Personnel
GRAND TOTAL

226.124

113,3t2
217,421

331,131

0

.,

-~

228,134' , 34OAOZ

113,468

552,883

m.2.s

530,500

530,500

530,500

64,356

22,363

22,363

594,851

892,215

530,500
64,356

276,432

"*-.

1QO,i73

>~. ~
fii

0
:!o ~'. ~.
202,1~ .

557,_ ."

;278,2J7

, :1<1' ',~"
-.076
",

'11

_,,~ ~538

Revenue

New State Appropriation

557,025

557,025

IUlrTyOl.'er ::state
Appropriation

New Matching Funds
\"arryover!rom Pre\l1OUS
Matching Funds

265,250
32,178
I '"

Total Revenue

·297~

"

6M.8I6.

265,250

265,250

32,178

11,182

892,284

27&,q2

0

265,250
. ,
>

552,863

278,513

278,513

0

11,182


829,295 1 · ~,3
'

[..,:f,..
,

I'
~,Cl25 .

- '.

"'i

". 8IlI,sae

